Summary:
A Randomized, Double-blind, Parallel-group, Vehicle-controlled, Multicenter Study in the Treatment of Scalp Psoriasis
Qualified Participants Must:
• Be 18 years of age or older
•
Female Subjects of childbearing potential (excluding women who are or premenarchal, surgically sterilized or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to 30 days after the last administration of study drug. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera (stabilized for at least 3 months), NuvaRing (vaginal contraceptive), Implanon (contraceptive implant), double barrier methods (e.g. condom and spermicide), IUD, or abstinence
•
Sign the Informed Consent Form
•
Have a clinical diagnosis of stable (at least 6 months) scalp psoriasis involving at least 10% of the scalp and clinical signs of psoriasis vulgaris on trunk and/or limbs
•
Agree to avoid tanning booths, sun lamps and excessive non-prescription UV light exposure (including natural sunlight) during the study
•
Be currently in general good health and free from any clinically significant disease, other than scalp psoriasis and psoriasis vulgaris, that may interfere with the study evaluations
•
Be willing and able to understand and comply with the requirements of the study, apply IP as instructed, attend required study visits, comply with study prohibitions, and be able to complete the study
Qualified Participants May Receive:
- Compensation for Time and Travel, If Qualified
- Study-related medication or placebo
- Physical exam by a licensed physician